Recommendation ID
NG191/9
Question

What is the clinical and cost effectiveness of budesonide for treating COVID-19 in the community in adults, young people and children?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcome)


P: Adults, young people and children who have COVID-19 and are not in hospital
Subgroups of particular interest:
• People 18 to 49 years
• Children and young people


I: Inhaled budesonide


C: Inhaled placebo (to accommodate blinding)


O:
• All-cause mortality
• Hospitalisation
• Need for oxygen therapy (including thresholds for this decision)
• Costs of treatment
• Time to recovery
• Health-related quality of life
• Adverse events


Source guidance details

Comes from guidance
COVID-19 rapid guideline: managing COVID-19
Number
NG191
Date issued
March 2021

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 12/11/2021